A DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, ORAL, MULTIPLE-DOSE, PARALLEL, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF ENDOXIFEN IN BIPOLAR I DISORDER PATIENTS - NA

Trial Profile

A DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, ORAL, MULTIPLE-DOSE, PARALLEL, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF ENDOXIFEN IN BIPOLAR I DISORDER PATIENTS - NA

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Endoxifen (Primary)
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Intas Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top